Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc. (AMLX) Stock Overview

Explore Amylyx Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.

AMLX●NASDAQ
HealthcareBiotechnology
$39.66
$1.06(2.75%)
U.S. Market opens in 15h 41m

Amylyx Pharmaceuticals, Inc. (AMLX)

Meyka AI Score

Z

Key Financials

Market Cap4.4B
P/E Ratio-26.93
EPS (TTM)$-1.50
ROE-0.53%
Fundamental Analysis

AI Price Forecasts

1 Month$26.49
3 Months$25.85
1 Year Target$19.63

AMLX Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Amylyx Pharmaceuticals, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of AMLX on the NASDAQ shows an RSI of 85.99, suggesting the stock is in a an overbought condition. Our forecasting models predict a 12-month price target of $19.63 for the NASDAQ listing.

Key metrics behind Amylyx Pharmaceuticals, Inc.'s NASDAQ-traded stock include a P/E ratio of -26.93 and a market capitalization of 4.4B. Combined with our AI analysis, these give both institutional and retail investors a clear view of AMLX on the NASDAQ.

Price Performance (NASDAQ: AMLX)

1-Day Change
2.75%
5-Day Change
77.45%
1-Month Change
127.28%
3-Month Change
191.40%
6-Month Change
183.08%
Year-to-Date (YTD) Change
228.31%
1-Year Change
393.90%
3-Year Change
86.20%
5-Year Change
119.48%
All-Time (Max) Change
119.48%

Contact Information

https://amylyx.com
617 682 0917
55 Cambridge Parkway, Cambridge, MA, 02142

Company Facts

1,360 Employees
IPO DateJan 7, 2022
CountryUS
Actively Trading

Frequently Asked Questions